

Intracavitary lesion caused by bladder wall stone and mimicking bladder tumor

Ibrahim Topcu¹, Fatih Oguz¹, Ilhan Gecit¹, Fatih Sancaktar¹, Ayse Nur Akatli²

¹Inonu University, Faculty of Medicine, Department of Urology, Malatya, Turkey

²Inonu University, Faculty of Medicine, Department of Pathology, Malatya, Turkey

Copyright © 2019 by authors and Annals of Medical Research Publishing Inc.

Abstract

We present a 28 year-old patient with incidental intramural stone covered by bladder mass. The pathology was rarely seen cystitis glandularis with intestinal metaplasia. During cystoscopy, stone was not seen, we resected the mass than stone was appeared in buried into the wall and removed from the bladder wall. The stone was fragmented with holmium laser. The pathology of the mass was cystitis glandularis with intestinal metaplasia which is rarely seen and may be malign by the time. We followed up the patient with cystoscopy every 3 months and no recurrences was detected.

Keywords: Bladder tumor, eosinophilic cystitis, bladder stone

INTRODUCTION

Bladder lesions can be benign and malignant increases with age. Urothelial carcinomas are the most common malign bladder lesion (> 90%). However, some urothelial or non-urothelial lesions mimic carcinoma and may cause problems in differential diagnosis (1). To distinguish these tumor-like lesions from malign lesions is undoubtedly important for the treatment and follow-up of the patient.

Many lesions, such as chronic cystitis, eosinophilic cystitis, cystitis glandularis, cystitis cystica, intestinal metaplasia, can mimic urothelial carcinoma. Cystitis cystica, cystic enlargement of the islands and eosinophilic secretory in the luminal cavities and cystitis glandularis define the appearance of a columnar or cuboidal appearance of these luminal cells in the glands, which are distinct apical cytoplasm (2,3). In the presence of goblet cells between luminal cells is called intestinal type cystitis glandularis and this has more diagnostic problems than the classical type of cystitis glandularis because it is miscible with

adenocarcinoma.

Intestinal metaplasia (IM) has an incidence of between 0.1% and 0.9%. IM is often associated with chronic inflammation of the urothelium (4-6). IM can be asymptomatic or frequently presents with hematuria or voiding symptoms. On cystoscopy, IM can be seen in form of solid or papillary lesions which can mimic urothelial carcinoma. But IM may be seen both in the normal bladder and in association with adenocarcinoma of the bladder (5-7). In adenocarcinoma, we expect more nuclear atypia, mitosis and deep lamina propria invasion by irregular glands (1,3,8).

The relationship between cystitis glandularis with intestinal metaplasia and tumor development is controversial. In some studies, no association between IM and a risk for the development of adenocarcinoma have shown in long-term follow-up (9,10). But still IM rarely shows dysplastic changes such as those seen in the gastrointestinal tract. Besides some have revealed a relationship between adenocarcinoma and cystitis glandularis with IM (3).

Received: 15.04.2019 **Accepted:** 25.09.2019 **Available online:**

Corresponding Author: Ibrahim Topcu

E-mail: ibrahimtopcu15@hotmail.com

In another study with 250 patient, 20 of them had Intestinal metaplasia with dysplasia and with concurrent adenocarcinoma in eight of 20 (40%) cases (11).

Consequently, these patients should not be removed from follow-up. We presented a case of cystitis glandularis and intestinal metaplasia due to intraluminal stone irritation.

Case Report

A 28-year-old male patient was admitted to the emergency department with a car accident. There was only smoking as a risk factor. On the abdominal CT scan of the patient, only a bladder stone about 2 cm is detected (Picture 1). So the patient referred to our clinic. We performed an




Figure 1. Bladder stone seen on abdominal CT



Figure 2. Cystoscopic view of the lesion




Figure 3. Bladder stone buried into the mass




Figure 4. Glandular structures demonstrating urothelial epithelium and goblet cells, and showing colonic mucosa like features in the lamina propria of the bladder (H&E,x40)

ultrasound image and saw suspected papillary mass extending bladder lumen. Then cystoscopy was done under spinal anesthesia, a well-circumscribed solid-based mass extending to the bladder lumen in the right orifice localization detected (Picture 2). During the resection of the mass, we saw a 2 cm stone buried into the bladder wall bottom of the mass (Picture 3). Then stone removed and the procedure terminated after taking as a separate example from the base of the mass. Pathological samples are shown in Picture 4.

There were no complications in the postoperative follow-up and the patient was discharged 3 days later

His pathology result was reported as cystitis glandularis and intestinal metaplasia. Control cystoscopies were performed every 3 months and no mass formation was observed. The patient is still under follow up.

DISCUSSION

It is unusual to see cytological findings of glandular cells in a urine specimen (12,13). The differential diagnosis of this includes cystitis cystica, cystitis glandularis (with or without intestinal metaplasia), villous adenoma of the bladder, in situ and infiltrating adenocarcinoma or rarely urothelial carcinoma with aberrant glandular differentiation (14). Cystitis glandularis has focal or diffuse glandular metaplasia of the urinary epithelium, (15) either due to chronic irritation of the urothelium or changes in the Von Brunn nests. The cells can change into cuboidal or columnar form and may produce mucin, taking on the appearance of intestinal-type goblet cells. So this type of variant is called cystitis glandularis with intestinal metaplasia (IM). Despite the urothelial origin, both bladder adenocarcinoma and cystitis glandularis stain positive for intestinal markers and are negative for urothelial marker most of time (16).

They are often placed in the bladder trigone, but also seen in the ureter and renal pelvis (17). The incidence of IM is 0.1–0.9% and increases with age; most commonly seen at fifth and sixth decades (17,18). Many factors that cause chronic irritation have been charged in the etiology; such as bladder exstrophy, bladder and kidney stone and neurogenic bladder (18).

There is contradictory evidence of whether IM is a premalignant or purely benign lesion. In some studies, IM has an association with adenocarcinoma (9,10,19). Smith et al showed IM concurrently with adenocarcinoma or urothelial carcinoma in 37% of patients but none of the patients with IM developed subsequent carcinoma (10). Likewise, in another study, there was no development of bladder carcinoma in long-term follow-up of 53 patients with intestinal metaplasia (9). Besides, a study with

250 patient, 20 of them had Intestinal metaplasia with dysplasia and with concurrent adenocarcinoma in eight of 20 (40%) cases (11).

Cystitis glandularis is sometimes a proliferative disease. When there is recurrence, antibiotics, NSAIDs, anti-allergy drugs and repeated resection can be done (20) but this disease may be resistant to these treatments. Takizawa et al. used celecoxib, one of COX-2 inhibitors, in a patient with repeated disease many time and showed no recurrence with this oral treatment (21). So this treatment can be used in resistant cases.

Additionally, as the natural history of IM is poorly understood, these patients should be followed up with either endoscopic or radiological surveillance until the evidence is more robust.

Competing interests: The authors declare that they have no competing interest

Financial Disclosure: The authors received no financial support for the research, authorship, and/or publication of this article.

Ethical approval: not necessary for case report

Ibrahim Topcu ORCID:0000-0002-6526-0255

Fatih Oguz ORCID:0000-0001-7292-0306

Ilhan Gecit ORCID:0000-0001-7329-6971

Fatih Sancaktar ORCID:0000-0001-5688-4739

Ayşe Nur Akatlı ORCID:0000-0002-9677-2456

REFERENCES

1. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. *Ann Oncol* 2010;21:1323–60.
2. Idrees MT, Ulbright TM, Oliva E, et al. The world health organization 2016 classification of testicular non-germ cell tumors: a review and update from the International Society of Urological Pathology Testis Consultation Panel. *Histopathology* 2017;70:513–21.
3. Chiodini S, Luciani LG, Cai T, et al. Unusual case of locally advanced and metastatic paratesticular liposarcoma: a case report and review of the literature. *Arch Ital Urol Androl* 2015;87:87–89.
4. Garcia Morua A, Lozano Salinas JF, Valdes Sepulveda F, et al. [Liposarcoma of the espermatic cord: our experience and review of the literature]. *Actas Urol Esp* 2009;33:811–15.
5. Fitzgerald S, Maclennan GT. Paratesticular liposarcoma. *J Urol* 2009;181:331–32.
6. Sherman KL, Wayne JD, Chung J, et al. Assessment of multimodality therapy use for extremity sarcoma in the United States. *J Surg Oncol* 2014;109:395–404.
7. Kanso C, Roussel H, Zerbib M, et al. [Spermatic cord sarcoma in adults: diagnosis and management]. *Prog*

- Urol 2011;21:53-8.
8. Li F, Tian R, Yin C, et al. Liposarcoma of the spermatic cord mimicking a left inguinal hernia: a case report and literature review. *World J Surg Oncol* 2013;11:18.
 9. Goldberg BR. Soft tissue sarcoma: An overview. *Orthopaedic Nursing* 2007;26:4-11.
 10. Armitage JO. My treatment approach to patients with diffuse large B-cell lymphoma. *Mayo Clin Proc* 2012;87:161-71.
 11. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. *Cancer* 2007; 110:652-59.
 12. Rotaru I, Nacea JG, Foarfa MC, et al. Primary diffuse large B-cell lymphoma of the testis. *Rom J Morphol Embryol* 2018;59:585-9.
 13. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood* 2007;109:1857-61.
 14. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. *Lancet Oncol* 2013;14:525-33.
 15. Hammond WJ, Farber BA, Price AP, et al. Paratesticular rhabdomyosarcoma: Importance of initial therapy. *J Pediatr Surg* 2017;52:304-8.
 16. Lei WH, Wu WF, Zhen JY, et al. Alveolar paratesticular rhabdomyosarcoma mimicing epididymitis: Case report and literature review. *Medicine (Baltimore)* 2018;97:11164.
 17. Matsumoto F, Onitake Y, Shimada K. Paratesticular Rhabdomyosarcoma Presenting With a Giant Abdominoscrotal Hydrocele in a Toddler. *Urology* 2016;87:200-1.
 18. Arisan S, Akbulut ON, Cakir OO, et al. Primary adenocarcinoma of the epididymis: case report. *Int Urol Nephrol* 2004;36:77-80.
 19. Zou ZJ, Xiao YM, Liu ZH, et al. Clinicopathological Characteristics, Treatment, and Prognosis of Rarely Primary Epididymal Adenocarcinoma: A Review and Update. *Biomed Res Int* 2017;2017:4126740.
 20. Foell JL, Hesse M, Volkmer I, et al. Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumor-associated cancer/testis antigen. *Pediatr Blood Cancer* 2008;51:228-34.
 21. Mahlendorf DE, Staeger MS. Characterization of Ewing sarcoma associated cancer/testis antigens. *Cancer Biol Ther* 2013;14:254-61.
 22. Tanik S, Zengin K, Albayrak S, et al. Cutaneous Ewing's sarcoma secondary to chemotherapy given for testis tumor: Case report. *Int J Surg Case Rep* 2014; 5:972-74.
 23. Parada D, Godoy A, Liuzzi F, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney. An infrequent finding. *Arch Esp Urol* 2007;60:321-25.
 24. Mani S, Dutta D, De BK. Primitive neuroectodermal tumor of the liver: a case report. *Jpn J Clin Oncol* 2010;40:258-62.
 25. Siraj F, Sharma S, Rai CB, et al. Primary high grade testicular leiomyosarcoma: A rare malignancy in a young male. *Turk J Urol* 2018;44:178-81.
 26. Coleman J, Brennan MF, Alektiar K, et al. Adult spermatic cord sarcomas: management and results. *Ann Surg Oncol* 2003;10:669-75.
 27. Khoubehi B, Mishra V, Ali M, et al. Adult paratesticular tumors. *BJU Int* 2002;90:707-15.
 28. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. *Sarcoma Meta-analysis Collaboration. Lancet* 1997;350:1647-54.
 29. da Fonseca LG, Marques DF, Takahashi TK, et al. Malignant paratesticular mesothelioma. *Autops Case Rep* 2014;4:45-51.